At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients With Tumors With cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuorendocrine Tumor)
In Brief
A Phase 2 clinical trial evaluating Biopsy Procedure, Biospecimen Collection, and 5 other interventions for Advanced Lymphoma and 4 related conditions. Active but no longer recruiting, targeting 10 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial tests how well sunitinib in treating patients with cancer that has certain genetic changes. Sunitinib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the cKIT gene. It works by blocking the action of mutated cKIT that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.
Study Details
Timeline
Interventions
Undergo biopsy
Undergo blood sample collection
Undergo CT scan
Undergo ECHO
Undergo MRI
Undergo nuclear study
Given PO